<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01510093</url>
  </required_header>
  <id_info>
    <org_study_id>2011/1811</org_study_id>
    <nct_id>NCT01510093</nct_id>
  </id_info>
  <brief_title>Diurnal Variation of Exogenous Peptides (Endogenous Insulin Jurgita II)</brief_title>
  <official_title>Interactions Between Exogenous Insulin Aspart, Endogenous Insulin and Plasma Glucose in Type 2 Diabetes Mellitus Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aarhus University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory trial with two cross-over arms investigating pharmacokinetic profiles
      of endogenous and exogenous insulin in type 2 diabetes mellitus patients treated with
      continuous subcutaneous Insulin Aspart infusion and combined with or without intravenous
      glucose infusion. The order of treatment session will be randomised.

      Hypotheses:

        1. Secretion of endogenous insulin depends on exogenous insulin supply

        2. Secretion of endogenous insulin is depends on plasma glucose levels
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are a screening visit and two treatment sessions:

      Session A: Treatment with Insulin Aspart 1.5 IE/time overnight without intravenous glucose
      infusion Session B: Treatment with Insulin Aspart 1.5 IE/time overnight with intravenous
      glucose infusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profiles of endogenous insulin and Insulin Aspart</measure>
    <time_frame>10 hours</time_frame>
    <description>Pharmacokinetic profiles of endogenous insulin and Insulin Aspart in type 2 diabetes melitus patients treated with continuous subcutaneous Insulin Aspart infusion by insulin pump and combined with or without intravenous supply of glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic glucose profiles</measure>
    <time_frame>10 hours</time_frame>
    <description>Pharmacodynamic glucose profiles after treatment with Insulin Aspart administred by insulin pump as a continuous subcutaneous infusion .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Insulin Aspart without glucose supply</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight without intravenous glucose supply</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Aspart with glucose supply</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Treatment with continuous subcutaneous Insulin Aspart 0.5-1.5 IE/time infusion overnight combined with intravenous glucose supply</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart 100 IE/ml</intervention_name>
    <description>1.5 IE/hour/subject/visit. Each vist takes 10 hours</description>
    <arm_group_label>Insulin Aspart without glucose supply</arm_group_label>
    <arm_group_label>Insulin Aspart with glucose supply</arm_group_label>
    <other_name>NovoRapid 100 IE/ml</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with type 2 diabetes mellitus

          -  Insulin-naive patients

          -  HbA1C &lt; 9%

          -  Women and men &gt;= 35 and &lt;= 75 years old

          -  BMI 25-42 kg/m2, both values are included

        Exclusion Criteria:

          -  Suspected or known allergy to the trial drug or similar medications

          -  Treatment with hte drugs that after Investigator judgment could potentially interfere
             with plasma glucose levels

          -  Heart: Unstable angina pectoris, acute myocardial infarction within the last 12 months

          -  Severe uncontrolled hypertension with blood pressure in lying position &gt; 180/110 mmHg

          -  Impaired liver function with liver parameters more than 2 times above the upper normal
             limit according to the local laboratory

          -  Impaired kidney function with eGFR &lt; 50 ml/min according to the local laboratory

          -  Pregnancy, lactation or desire for pregnancy in the study period and for women in
             childbearing age without adequate contraception-adequate contraception is:
             sterilisation, hysterectomy or current use of contraceptive pills, coil, gestagen
             depot injection, subdermal implantation, hormonal vaginal ring and transdermal depot
             patch.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jurgita Janukonyte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Aarhus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology and Internal Diseases</name>
      <address>
        <city>Aarhus C</city>
        <state>Central Denmark Region</state>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2012</study_first_submitted>
  <study_first_submitted_qc>January 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2012</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aarhus University Hospital</investigator_affiliation>
    <investigator_full_name>Jurgita Janukonyte</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes mellitus, endogenous insulin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin, Long-Acting</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

